AGC Biologics to increase capacity for pDNA and mRNA manufacturing in Heidelberg
![](/46/pdcnewsitem/11/41/75/agc.jpeg)
The expansion plans include an additional manufacturing line, a new cleanroom and a new process development lab
Global biopharmaceutical CDMO AGC Biologics has laid out plans to expand its Heidelberg facility to increase manufacturing capacities for plasmid-DNA (pDNA) and messenger RNA (mRNA) projects.
By adding an additional GMP manufacturing line, the company will boost its current 100-L and 1,000-L manufacturing capacities for a variety of different biologics projects.
The expansion includes a new GMP cleanroom for mRNA development and manufacturing, a new process development lab for microbial protein and cell and gene therapy projects, and additional warehouse capacity.
The expanded capabilities will also allow the CDMO to meet the increasing demands of the rapidly growing cell and gene therapy market.
This announcement is the latest in a series of investments AGC Biologics has made this year to expand its offerings and global footprint:
- Last month, the company broke ground on a new multipurpose facility in Copenhagen, Denmark that will grow AGC Biologics’ global capacity.
- Approximately one month ago, the company acquired the previously owned Novartis Gene Therapies' Longmont, CO facility, helping it to expand its cell and gene therapy capabilities footprint into the US.
- Earlier this year, the company expanded its C> facility in Milan, Italy as well, adding additional capacity and viral vector suspension capabilities.
In a statement, AGC Biologics said it anticipates the Heidelberg facility's new capabilities will be fully operational in 2023.
![AGC Biologics](https://www.cphi-online.com/c272056th_S-comp272056.jpg)
Related News
-
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News Sanofi to collaborate with OpenAI and Formation Bio
Pharmaceutical giant Sanofi have announced a collaboration with Formation Bio and OpenAI to build AI-powered software for accelerated drug development. -
News AstraZeneca to build billion-dollar ADC manufacturing site in Singapore
The British-Swedish drugmaker has announced plans to build a US$1.5 billion facility in Singapore for the manufacturing of antibody–drug conjugates (ADCs) to complement their existing cancer drug portfolio. -
News Women in Pharma: Delivering personal and professional success
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Eisai begins US FDA rolling submission for Alzheimer’s drug Leqembi
Japanese drugmaker Eisai, in partnership with Biogen, have announced that they have begun submitting data on a rolling basis to the US FDA for a marketing application of a subcutaneous injectable form of Alzheimer’s drug Leqembi.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance